The Agreement on Trade-Related Intellectual Property Rights (TRIPS) is an agreement of international law between all World Trade Organization (WTO) member states. It sets minimum standards for the regulation of different forms of intellectual property by national governments, as is the case for nationals of other WTO member states.  The TRIPS agreement was negotiated at the end of the Uruguay Round of the General Agreement on Tariffs and Trade (GATT) between 1989 and 1990 and is managed by the WTO. Despite the Doha Declaration, many developing countries have been under pressure in recent years to adopt or implement even stricter or more restrictive conditions in their patent laws than those under the TRIPS agreement – these provisions are called “TRIPS plus.” Countries are not required to do so under international law, but many countries, such as Brazil, China or Central America, have had no choice but to adopt them under trade agreements with the United States or the European Union. These have disastrous effects on access to medicines. Trips-plus conditions, which impose standards beyond TRIPS, have also been verified.  These free trade agreements contain conditions that limit the ability of governments to introduce competition for generic drug manufacturers. In particular, the United States has been criticized for promoting protection far beyond the standards prescribed by the TRIPS. The U.S. free trade agreements with Australia, Morocco and Bahrain have expanded patentability by making patents available for new uses of known products.
 The TRIPS agreement authorizes the granting of compulsory licences at the discretion of a country. The terms of trips plus in the U.S. Free Trade Agreement with Australia, Jordan, Singapore and Vietnam have limited the application of mandatory licences to emergencies, remedies for cartels and abuse of dominance, and cases of non-commercial public use.  1. Members agreed to engage in negotiations to strengthen the protection of the various geographical indications, in accordance with Article 23. Paragraphs 4 to 8 below cannot be used by a member to refuse to negotiate or conclude bilateral or multilateral agreements. As part of these negotiations, members are prepared to consider the subsequent applicability of these provisions to the individual geographical indications whose use has been the subject of these negotiations. Since the TRIPS agreement came into force, it has been criticized by developing countries, scientists and non-governmental organizations.
While some of this criticism is generally opposed to the WTO, many proponents of trade liberalization also view TRIPS policy as a bad policy. The effects of the concentration of WEALTH of TRIPS (money from people in developing countries for copyright and patent holders in industrialized countries) and the imposition of artificial shortages on citizens of countries that would otherwise have had weaker intellectual property laws are common bases for such criticisms.